Jane Blazeby - Concepedia

Author

Jane Blazeby

Also Known As

Altman, Douglas G., Amanda Owen-Smith, Barnaby Reeves, Barry G. Main, Barry Main, Blazeby, J, Blazeby, JM; id_orcid 0000-0002-3354-3330, Blazeby, Jane, Bluebelle Study Management Group, C Billyard

871

Publications

47.5K

Citations

H-Index

144

Concepts

All Affiliations

University of Bristol University Hospitals Bristol NHS Foundation Trust University of Oxford University of Liverpool Bristol Royal Infirmary

About

Jane Blazeby is an author at University of Bristol specializing in medicine, outcomes research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	20	23	1.2K
2	Management	2	2	68
3	Arts	1	1	279
4	Business	1	1	35
5	Engineering	1	1	34

Jane Blazeby

283

Publications

33.8K

Citations

H-Index

Page 1

	Year	Citations
A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance Kathryn Skivington, Lynsay Matthews, Sharon Simpson, BMJ	2021	5.3K
Developing core outcome sets for clinical trials: issues to consider Paula Williamson, Douglas G. Altman, Jane Blazeby, Trials	2012	1.6K
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer Jenny Donovan, Freddie C. Hamdy, J. Athene Lane, New England Journal of Medicine	2016	1.3K
Reporting of Patient-Reported Outcomes in Randomized Trials Melanie Calvert, Jane Blazeby, Douglas G. Altman, JAMA	2013	1.3K
Core Outcome Set-STAndards for Development: The COS-STAD recommendations Jamie J Kirkham, Douglas G. Altman, Jane Blazeby, PLoS Medicine	2017	713
The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care Mogens Grøenvold, Morten Aagaard Petersen, Neil K. Aaronson, European Journal of Cancer Palliative CareMedicineEnd-of-life CareCancer ManagementSymptomatic Treatment	2005	661
Challenges in evaluating surgical innovation Patrick Ergina, Jonathan Cook, Jane Blazeby, The Lancet Innovation EvaluationOutcomes ResearchSurgeryMedicinePlastic Surgery	2009	625
Core Outcome Set–STAndards for Reporting: The COS-STAR Statement Jamie J Kirkham, Sarah L. Gorst, Douglas G. Altman, PLoS Medicine	2016	605
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial Hugo Ford, Andrea Marshall, John Bridgewater, The Lancet Oncology	2013	597
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, The Lancet Long CovidAntimicrobial StewardshipAntibioticsClinical InfectionPlatform Trial	2021	555

Page 1